Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals insider plans another stock sale under Rule 144. A holder has filed to sell 8,353 shares of Ionis common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $636,626.29. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation.
The notice also lists recent sales in the past three months for the same account holder. Shannon Devers sold 16,777 shares of common stock on 11/25/2025 for gross proceeds of $1,342,160.00, and 44,199 shares on 01/07/2026 for gross proceeds of $3,760,522.76 through Stifel Nicolaus & Company Inc. The filer represents that they are not aware of undisclosed material adverse information about Ionis.
Ionis Pharmaceuticals reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA. These figures give an early view of how the medicine performed commercially during 2025.
The company stated that these TRYNGOLZA sales numbers are unaudited, may be adjusted, and are being shared ahead of a fuller financial update. Ionis plans to release complete financial results, including more detailed performance information, in February 2026.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple option exercises and related stock sales. On January 7, 2026, Devers exercised several non-qualified stock options to buy Ionis common stock at exercise prices ranging from $32.60 to $56.78, including blocks of 25,545, 9,264, 3,829, 3,460, and 2,101 shares. On the same day, Devers sold corresponding amounts of common stock, with weighted average sale prices reported around $84–$85 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 3, 2024. After these transactions, Devers directly beneficially owned 17,494 shares of Ionis common stock.
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, received a new stock option award. On 01/02/2026 she was granted a non-qualified stock option to buy 9,100 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.
The option was not exercisable for any shares on the grant date. According to the vesting schedule, 25% of the shares will vest and become exercisable on 01/02/2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments over the following three years.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
